STOCK TITAN

Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that its CEO, Mark Gergen, will participate in a fireside chat during the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET. The event focuses on advancements in cell and gene therapies for cancer and rare diseases. Investors can access a live webcast of the presentation on Poseida's website, with a replay available for 90 days post-event. Poseida is recognized for its proprietary genetic editing platforms aimed at improving patient outcomes in oncology.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's Chief Executive Officer, Mark Gergen, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET.

A webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Poseida's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral Super piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. The Company has formed global strategic collaborations with Roche and Takeda to unlock the promise of cell and gene therapies for patients. Learn more at www.poseida.com and connect with Poseida on Twitter and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-hc-wainwright-cell-therapy-virtual-conference-301746302.html

SOURCE Poseida Therapeutics, Inc.

FAQ

What is the event Poseida Therapeutics is participating in?

Poseida Therapeutics will participate in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023.

Who is presenting for Poseida Therapeutics at the conference?

Mark Gergen, the CEO of Poseida Therapeutics, will present at the conference.

What time is Poseida's presentation at the conference?

Poseida's presentation is scheduled for 11:00 AM ET on February 28, 2023.

Where can I find the webcast of Poseida's conference presentation?

The webcast will be available on Poseida's website in the Investors & Media section.

How long will the replay of Poseida's webcast be available?

The replay of the webcast will be available for approximately 90 days after the presentation.

What is Poseida Therapeutics known for?

Poseida Therapeutics is known for developing cell and gene therapies for cancer and rare diseases using proprietary genetic editing technologies.

Poseida Therapeutics, Inc.

NASDAQ:PSTX

PSTX Rankings

PSTX Latest News

PSTX Stock Data

916.19M
70.29M
27.64%
58.48%
4.73%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO